期刊文献+

RFT2在胃癌中的表达及其临床意义

Expression of RFT2 in gastric cancer and its clinicopathological significance
暂未订购
导出
摘要 目的探讨胃癌组织中核黄素转运蛋白2(riboflavin transporter-2,RFT2)表达及其与胃癌临床病理参数之间的关系。方法取胃癌石蜡包埋组织标本及癌旁胃黏膜组织标本各60例,用免疫组织化学方法检测癌组织RFT2蛋白表达水平。结果 RFT2蛋白在胃癌组织中的表达水平低于癌旁正常胃黏膜组织(P<0.05)。胃癌组织中RFT2蛋白表达水平在胃癌的分化程度、TNM分期、Lauren组织学分型方面差异有统计学意义(均P<0.05),在患者性别、民族、年龄、有无淋巴结转移、肿瘤大小方面差异无统计学意义(均P>0.05)。结论 RFT2蛋白表达在人胃癌组织中表达显著下降,其表达与肿瘤组织分化程度及TNM分期密切相关。 Objective To investigate the expression of riboflavin transporter-2( RFT2) in gastric cancer and its clinicopathological significance. Methods Sixty paraffin-embedded,formalin-fixed gastric cancer samples and 60 tumoradjacent stomach mucous tissues were collected. Immunohistochemical staining was employed to detect the expression level of RFT2 in the tissues. Results The expression of RFT2 was significantly lower in gastric cancer tissue than that in adjacent normal tissue( P〈0. 05). The expression of RFT2 was significantly different in cases with different differentiation degree,TNM stage and Lauren histologic type( P〈0. 05),but not significantly different in cases with different gender,ethnicity,age,lymph node metastasis or tumor size( P〉0. 05). Conclusion The expression of RFT2 is down-regulated in gastric cancer tissue,and it is correlated with both histological differentiation degree and TNM stage of the tumor.
出处 《实用肿瘤杂志》 CAS 2016年第2期154-157,共4页 Journal of Practical Oncology
关键词 胃肿瘤/病理学 免疫组织化学 预后 核黄素转运蛋白2 stomach neoplasms/pathology immunohistochemistry prognosis riboflavin transporter-2
  • 相关文献

参考文献8

  • 1李晓芬,崔学芳,李晶晶,袁瑛.胃癌术后2种辅助化疗方案的疗效及安全性分析[J].实用肿瘤杂志,2013,28(3):309-311. 被引量:6
  • 2Edge SB, Byrd DR,Compton CC,et al. AJCC cancer stag-ing manual [ M ]. 7th ed. New York : Springer-Verlag,2010:117 -126.
  • 3杨晓辉,蔡慧珍,汪岭,马丽霞.回族血清中微量元素含量与胃癌的相关性研究[J].实用肿瘤杂志,2012,27(5):499-501. 被引量:3
  • 4Eussen SJ, Vollset SE,Hustad S,et al. Vitamins B2and B6 and genetic polymorphisms related to one-carbonmetabolism as risk factors for gastric adenocarcinoma inthe European prospective investigation into cancer and nu-trition [J ]. Cancer Epidemiol Biomarkers Prev, 2010, 19(1):28 -38.
  • 5Siassi F,Ghadirian P. Riboflavin deficiency and esophage-al cancer: a case control-household study in the CaspianLittoral of Iran [ J ]. Cancer Detect Prev,2005 ,29 ( 5 ):464 一469.
  • 6Qiao YL, Dawsey SM, Kamangar F,et al. Total andcancer mortality after supplementation with vitamins andminerals : follow-up of the Linxian General Population Nu-trition Intervention Trial[ J]. J Natl Cancer Inst,2009,101(7):507 -518.
  • 7Dawsey SP, Hollenbeck A, Schatzkin A, et al. A pro-spective study of vitamin and mineral supplement use andthe risk of upper gastrointestinal cancers[ J]. PLoS One,2014,9(2) :e88774.
  • 8Bilici A, Sonkaya A, Ercan S,et al. The changing of ser-um vitamin B12 and homocysteine levels after gastrectomyin patients with gastric cancer : do they associate withclinicopathological factors [ J ]. Tumour Biol, 2015 , 36(2) :823 -828.

二级参考文献20

  • 1王孟才,张立,徐刚,王辉,宋连生.胃癌血清中24种元素临床流行病学研究[J].实用肿瘤学杂志,1996,10(3):3-4. 被引量:3
  • 2庞丹梅,邓燕明,林耀东,徐绮华.mFOLFOX6方案用于进展期胃癌术后辅助化疗的临床研究[J].实用癌症杂志,2007,22(3):269-270. 被引量:10
  • 3Zow czak M,Isk Te M ,Torlinskil, et al. Analysis of serum copper and zinc concentrations in cancer patients [ J ]. Biol Trace Elem Res,2001 , 1 (3) : 1.
  • 4孑L祥瑞.必须微量元素的营养生理及临床意义[M].合肥:安徽科技出版社,1982:155-158.
  • 5Enzinger PC,Burtness B, Hollis D, et al. CALGB 80403/ ECOG 1206: A randomized phase lI study of three standard chemotherapy regimens ( ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer [J]. J Clin Oncol (Meeting Abstracts),2010,28 ( 15 Suppl) :4006.
  • 6Mohammad HA, Magdy FM, Mahmoud OM. FOLFOX ( oxaliplatin and 5 fluorouracil/leucovorin ) in patients with untreated metastatic gastric adenocarcinoma. Phase [I study [ J]. Indian J Cancer,2011,48 (4) :460 - 465.
  • 7Xiang X J, Zhang L, Qiu F, et al. A phase 1I study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer [ J]. Chemotherapy ,2012,58 ( 1 ) : 1 - 7.
  • 8Bang Y J, Kim YW, Yang HK,et al. Adjuvant capecitabineand oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC) : a phase 3 open-label,randomized controlled trial [ J]. Lancet,2012,379(9813 ) :315 - 321.
  • 9Matsubara J,Shimada Y, Kato K, et al. Phase study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel as first-line therapy for advanced gastric cancer [ J ]. Oncology, 201 I, 81 ( 5-6 ) : 291 - 297.
  • 10lmalao M, Peng YF, [toh T, et al. A preliminary study ot single intraperitoneal administration of paclitaxel followed by sequential systemic chemotherapy with S-1 plus paclitaxel for advanced gastric cancer with peritoneal metastasis [ J]. Anticancer Res, 2012,32 (9):4071 - 4075.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部